Natural course of lower urinary tract symptoms following discontinuation of alpha-1-adrenergic blockers in patients with benign prostatic hyperplasia

Teruhiko Yokoyama, Toyohiko Watanabe, Takashi Saika, Yasutomo Nasu, Hiromi Kumon, Yoshiyuki Miyaji, Atsushi Nagai

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Objective: α1-adrenergic blockers (αb) remain the first-line therapy in men with lower urinary tract symptoms (LUTS). The current published work advocates continued use of αb for their effect to be maintained. However, some patients decide to discontinue use of the medication after their symptoms are relieved and can keep good conditions. In this study, we investigated the natural course of LUTS after the discontinuation of successful treatment of αb. Methods: Among 75 patients with LUTS who stopped αb medication once their symptoms improved, 60 patients (age, 50-87 years; median, 70) who could be followed for at least 12 months after discontinuation of αb were analyzed in this study. Evaluations included a clinical determination of the International Prostate Symptom Score (IPSS), peak flow rate (Qmax) and postvoid residual urine volume (PVR). Upon patient request or in cases of PVR more than 100 mL, administration of αb was resumed. Results: Eighteen out of the 60 patients (30%) asked for re-treatment within 12 months after discontinuation (re-treatment group). The other 42 patents were able to maintain good condition without medication (discontinuation group). The IPSS was 15.9, 8.7, 10.1, 10.2, 9.7, 8.8 and 9.0, on the first visit, just before discontinuation, and 1, 3, 6, 9 and 12 months after stopping treatment among the discontinuation group, respectively. Similarly, Qmax was 10.6, 14.8, 14.2, 14.3, 14.7, 13.2 and 13.6 mL/ s, respectively. Treatment periods, prostatic volume and peak flow rates just before discontinuation of medication differed significantly between the re-treatment and discontinuation group. Conclusions: In spite of the short follow-up periods, these results suggest that selected patients with relatively small prostatic volume and good flow rates after therapy can discontinue αb medication after their symptoms improve.

Original languageEnglish
Pages (from-to)598-601
Number of pages4
JournalInternational Journal of Urology
Volume14
Issue number7
DOIs
Publication statusPublished - Jul 1 2007

    Fingerprint

Keywords

  • Alpha-adrenergic antagonist
  • Discontinuation
  • Prostatic hyperplasia

ASJC Scopus subject areas

  • Urology

Cite this